Responses
Endometrial cancer
385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study
Compose a Response to This Article
Other responses
No responses have been published for this article.